Intellia Therapeutics Submits Rolling BLA for Lonvo-z, First In Vivo CRISPR Therapy for HAE

Intellia Therapeutics' rolling BLA submission to FDA for lonvoguran ziclumeran (lonvo-z) puts CMC teams and regulatory leads at the frontier of a manufacturing category with no established precedent: a systemically delivered, single-dose in vivo CRISPR/Cas9 therapy seeking approval under a biologics pathway.

The submission is supported by topline data from the global phase 3 HAELO trial (NCT06634420), which met its primary endpoint and all key secondary endpoints. The trial enrolled adults with type 1 and type 2 hereditary angioedema (HAE), randomised 2:1 to a 50 mg dose of lonvo-z or placebo, with attack frequency and attack-free status from weeks 5 through 28 serving as the principal measures. Placebo-arm participants were permitted to cross over at 28 weeks, a design feature that will require careful handling in the benefit-risk sections of the submission package.

For plant heads and QA directors, the manufacturing profile of lonvo-z concentrates risk in several areas simultaneously. The therapy relies on lipid nanoparticle (LNP) delivery to achieve systemic gene editing, a modality where batch-to-batch consistency, particle size distribution, and encapsulation efficiency carry direct sterility assurance and potency implications. Cold chain integrity across a global trial network spanning sites in Arizona, California, Colorado, Ohio, and Ontario adds a further layer of distribution complexity that will need to be reflected in validated shipping studies and comparability protocols within the BLA.

The rolling review mechanism FDA is applying here allows Intellia to submit completed modules as they are finalised rather than as a single package, a practical accommodation for novel modalities where CMC data generation and clinical data generation run in parallel. For regulatory affairs leads, that sequencing creates both an opportunity and an obligation: each module submitted becomes a fixed reference point, and any post-submission manufacturing changes will need to be managed against an evolving but partially locked dossier.

First patient dosing in HAELO was recorded in January 2025, with enrolment targeted for completion in the second half of that year, placing the submission timeline broadly consistent with a compressed development cycle for a gene editing asset of this complexity.

The completeness of the BLA package and FDA's review clock will serve as the first measurable checkpoint for how the agency processes CMC submissions for LNP-delivered in vivo gene editing therapies at commercial scale.

Source: CGTLive via cgtlive.com, May 15, 2026.